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Abstract
Reprogramming somatic cells from one cell fate to another can generate specific neurons suitable 
for disease modeling. To maximize the utility of patient-derived neurons, they must model not 
only disease-relevant cell classes but also the diversity of neuronal subtypes found in vivo and the 
pathophysiological changes that underlie specific clinical diseases. Here, we identify five 
transcription factors that reprogram mouse and human fibroblasts into noxious stimulus-detecting 
(nociceptor) neurons that recapitulate the expression of quintessential nociceptor-specific 
functional receptors and channels found in adult mouse nociceptor neurons as well as native 
subtype diversity. Moreover, the derived nociceptor neurons exhibit TrpV1 sensitization to the 
inflammatory mediator prostaglandin E2 and the chemotherapeutic drug oxaliplatin, modeling the 
inherent mechanisms underlying inflammatory pain hypersensitivity and painful chemotherapy-
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induced neuropathy. Using fibroblasts from patients with familial dysautonomia (hereditary 
sensory and autonomic neuropathy type III), we show that the technique can reveal novel aspects 
of human disease phenotypes in vitro.
Directed differentiation from pluripotent stem cells and lineage reprogramming of 
fibroblasts can both be used to derive a wide range of different neuronal subtypes1,2. While 
the known sequence of morphogen exposure and consequent molecular changes in the 
development of specific neurons can guide directed differentiation strategies, the selection 
of transcription factors for lineage reprogramming from fibroblasts remains essentially 
empirical. No single transcription factor has proved essential for driving cell fates in all 
neuronal reprogramming studies to date, despite the fact that specific factors such as Ascl1 
or Ngn2 seem particularly potent in deriving a range of different neuronal subtypes3. Brn2, 
Ascl1 and Myt1l (abbreviated BAM) generate generic neurons on their own4 and specific 
neuronal subtypes when combined with additional factors5,6. Moreover, the developmental 
stage at which a particular transcription factor acts in vivo may determine whether that factor 
facilitates or inhibits the patterning of reprogrammed neurons4,5.
Nociceptors are the first-order neurons in the pain sensory transduction pathway and play 
the critical initial step in the detection of noxious stimuli (nociception) and the development 
of inflammatory and neuropathic pain7. Nociceptor neurons employ a host of highly specific 
ionotropic receptors and ion channels, including TrpV1, TrpA1, TrpM8 and P2X3 receptors 
to transduce stimuli, as well as slow, tetrodotoxin (TTX)-resistant sodium channels (NaV1.8 
and NaV1.9) that generate their characteristic broad action potentials8. Efforts to derive 
nociceptors using a small molecule-based directed differentiation strategy from human 
neural crest precursors have produced neurons that recreate some but not all of these 
characteristic receptors and channels9.
Mutations in nociceptor-specific membrane proteins underlie a wide range of pain diseases, 
including rare but severe channelopathies due to NaV1.7 or TrpA1 mutations10, common 
small fiber neuropathies due to activating mutations in NaV1.7 or NaV1.811,12, as well as a 
variety of pain-predisposing polymorphisms13,14; however, the biological effects of these 
mutations on nociception have not been studied in human sensory neurons. Nociceptors 
normally activate only following intense, potentially damaging stimuli in order to provide a 
protective warning of imminent tissue injury. However, they also have the remarkable 
capacity to become sensitized after exposure to inflammatory mediators15,16 or by 
chemotherapeutic drugs17, resulting in a reduced activation threshold so that innocuous 
stimuli can generate a pain response. Pain hypersensitivity can play a physiologically useful 
role in minimizing further injury and in promoting healing once damage has occurred; 
however, such transient sensitization, when it persists, promotes the development of chronic 
pain.
Nociceptor neuron development occurs through dorsalization within the neural tube18, 
followed by neural crest induction and migration19 and then nociceptor specification within 
the still-multipotent neural crest lineage20. The generation of nociceptor progenitors 
expressing the TrkA neurotrophin receptor (Ntrk1) and postnatal nociceptors expressing 
TrpV1 requires the basic helix-loop-helix transcription factor Ngn1 (Neurogenin1), which is 
Wainger et al. Page 2
Nat Neurosci. Author manuscript; available in PMC 2015 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
normally present from approximately days E9–E13 in the embryonic mouse21. Although 
developing nociceptors express multiple Trk-family receptors, maturing nociceptors express 
only TrkA. Brn3a (POU4F1) promotes Runx1 expression, which together with Isl1 (Islet 1) 
and Klf7 maintain TrkA expression in developing nociceptors22–25. A subset of nociceptors 
that become the peptidergic subclass of nociceptors maintain TrkA expression and express 
calcitonin gene-related peptide (CGRP, CalcA) and substance P. For non-peptidergic 
nociceptors, most of which bind isolectin B4, the glial cell derived neurotrophic factor 
(GDNF) receptor Ret replaces TrkA in a process dependent on Runx1, and loss of Runx1 
markedly reduces TrpV1 expression23.
We set out to produce nociceptor neurons through transcription-mediated lineage conversion 
of fibroblasts. From an initial set of 12 factors, we find that expressing five factors is 
sufficient to generate functional mouse nociceptor neurons. In a direct comparison between 
the induced nociceptors and primary adult mouse nociceptors, we show that the induced 
neurons mimic bona fide nociceptors with regard to the function of the specific individual 
receptors and channels, such as TrpA1, TrpM8, P2X3 and NaV1.8, as well as with regard to 
the population diversity. We demonstrate that the induced neurons also model inflammatory 
peripheral sensitization, a critical process that underlies transient pain hypersensitivity and 
contributes to the pathological transition to chronic pain, as well as sensitization following 
exposure to the chemotherapeutic drug oxaliplatin. Finally, we derive human nociceptor 
neurons from patients with familial dysautonomia (FD) and show that these neurons reveal 
potentially disease-relevant phenotypes in vitro.
RESULTS
Selection and Optimization of Transcription Factors
We first developed nociceptor reporter mice by taking advantage of an existing TrpV1 Cre-
driver26 and floxed tdTomato mice to generate TrpV1-Cre+/−::tdTomato+/− reporter mice, 
from which we obtained mouse embryonic fibroblasts (MEFs). Activation of the tdTomato 
reporter signaled the conversion of the MEFs to TrpV1-expressing cells (Supplementary 
Fig. 1). We began with nine transcription factors selected to promote lineage conversion to 
nociceptors in combination with the three BAM factors (12 total, Table 1). These factors 
were chosen using a combination of the prior literature, transcription factor expression 
profiles in FACS-sorted adult mouse nociceptors (NaV1.8-positive) as compared to 
proprioceptors (parvalbumin-positive) (Chiu et al, submitted), an expression profile 
similarity to NaV1.8 in the BioGPS database27, and postnatal dorsal root ganglion (DRG) 
expression in the Allen Brain Atlas28.
As expected, there was no baseline activation of the tdTomato reporter in MEFs (not 
shown). Staining of MEFs for neuronal precursor markers using antibodies to Nestin, Sox1, 
and Ki67, as well as for neuron-specific class III β-tubulin (Tuj1), were all negative 
(Supplementary Fig. 2). After transducing the fibroblasts with a combination of all 12 
individual retroviruses containing the selected transcription factors, we detected a small 
number of tdTomato-positive cells with a neuronal morphology after two weeks 
(Supplementary Fig. 3a). In order to identify those transcription factors that were either 
critical for or inhibitory to lineage reprogramming into TrpV1-expressing cells, we then 
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sequentially eliminated each factor, one at a time. Surprisingly, the omission of some 
transcription factors strongly supported by the literature for a role in promotingTrpV1 
expression, such as Runx1, did not eliminate TrpV1 reporter expression (Supplementary Fig 
3b). In fact, omission of Brn3a led to a marked increase in the number of tdTomato-positive 
cells (Supplementary Fig. 3c). We identified from this iterative process three factors that 
were critical to the TrpV1 lineage reprogramming process in that their omission led to a near 
complete absence of tdTomato and neuronal Class III β-tubulin (Tuj1)-positive cells bearing 
a neuronal morphology: Ascl1, Myt1l and Klf7 (Supplementary Fig. 3d–f).
When we combined the three BAM factors with Isl2, Ngn1, and Klf7, we again observed 
only a small number of tdTomato, Tuj1-positive cells (Fig. 1a). Because prior studies5 and 
our initial drop out experiments detected specific factors that could inhibit the lineage 
reprogramming process, we performed single factor dropouts from these six factors and 
found that omission of Brn2 led to a striking increase in the number of tomato-positive 
neurons (Fig. 1b), giving a yield of approximately 14% of plated fibroblasts that were both 
tdTomato- and Tuj1-positive (less than 0.1% were tdTomato-positive but Tuj1-negative). 
Removal of any other factor from the six sharply reduced the number of tdTomato-positive 
neurons (Fig. 1c–h). Next, we evaluated Ngn1 alone and in combination with the BAM 
factors; however, the yield was much lower than with the optimized five factor combination 
(Supplementary Fig. 4). Indeed, further removal of any of the five factors resulted in a 
marked decrease in tdTomato, Tuj1-positive cells (Supplementary Fig. 5).
Molecular Characterization of Induced Mouse Nociceptors
To determine if tdTomato-positive reprogrammed neurons phenocopied bona fide 
nociceptors, we evaluated the expression of protein markers specific for nociceptor neurons. 
Nearly all tdTomato-positive neurons stained for the pan-neuronal marker Tuj1 and had a 
neuronal-like morphology with many long branching axons, and most Tuj1-positive neurons 
were tdTomato-positive (Fig. 2a). Staining with an anti-TrpV1 antibody confirmed the 
translation of the TrpV1 protein in the vast majority of tdTomato-positive neurons (Fig. 2b). 
In mouse dorsal root ganglia, most TrpV1-expressing neurons are C-fibers that express the 
marker peripherin (Prph)29, while only a small percentage of A-δ fibers are also TrpV1-
positive26. In the induced neurons, a majority of tdTomato-positive neurons expressed 
peripherin (66.9 ± 4.1%, n=16 wells from 4 separate transductions) (Fig. 2c) and many 
CGRP (22.3 ± 6.6%, n=4 wells from 2 separate transductions) (Fig 2d); however, a smaller 
number of cells stained for the intermediate filament NF200, a marker, in this context, of 
myelinated A-δ nociceptors (Fig. 2e). In contrast, the derived nociceptors did not stain for 
smooth muscle actin (SMA), a marker of muscle, despite reports of TrpV1 expression in 
muscle30 (Supplementary Fig. 6a,b). Furthermore, neurons derived from the three BAM 
factors did not express nociceptor markers, consistent with their high specificity 
(Supplementary Fig. 6c–g).
Because specific antibodies do not exist for many quintessential nociceptor proteins, we 
utilized quantitative RT-PCR to compare nociceptor marker mRNA levels in tdTomato-
positive induced nociceptors and tdTomato-positive adult mouse nociceptors relative to 
levels in MEFs (Fig. 2f). For this analysis, we used patch pipettes to pick tdTomato-positive 
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induced and primary mouse neurons, as well as MEFs, and plotted the levels of specific 
transcripts in induced and primary nociceptors relative to MEFs. The fibroblast marker 
S100A4 was expressed at a similar very low level in both the induced and primary 
nociceptors, consistent with a non-fibroblast identity of the induced nociceptors. NaV1.7 
(Scn9a), which is found in nociceptor and autonomic peripheral neurons, was present in both 
the induced and primary nociceptors, as was TrkA (NTRK1), which is turned on in 
developing nociceptors and persists in the peptidergic subset of mature nociceptors, 
although the expression of NaV1.7 and TrkA in the induced neurons was several fold less 
than in the primary DRGs. Together, these immunohistochemistry and PCR data suggest 
that the induced neurons express a complement of bona fide nociceptor-specific markers.
Functional Properties of Induced Mouse Nociceptors
In order to investigate the functional properties of the induced nociceptors, we performed 
calcium imaging with a battery of agonists and evaluated the number of responders within 
the tdTomato-positive population with a stable baseline and response to potassium chloride 
(KCl, which activates voltage-gated calcium channels through depolarization and serves as a 
measure of neuronal functional integrity) (Fig. 3a). We chose concentrations of agonists for 
TrpM8 (250 µM menthol), TrpA1 (100 µM mustard oil) and TrpV1 (1 µM capsaicin) that 
only activated their respective cognate receptors31. 39% of the cells responded to capsaicin, 
9% to mustard oil and 3% to menthol (Fig. 3a,b; n=227 tdTomato-positive cells that 
responded to KCl). We observed occasional cells that responded to both mustard oil and 
capsaicin, a single cell that responded to menthol and mustard oil but not capsaicin, and one 
cell that responded to all three agonists. We did not observe any tdTomato-positive cells that 
responded to menthol alone, but we did identify a small number of tdTomato-negative cells 
that responded to menthol but not the other Trp agonists (Supplementary Fig. 7a). In 
contrast, 0/50 KCl-responding neurons derived from the BAM factors alone responded to 
capsaicin (not shown). Using the same experimental procedure, we then asked how the 
frequencies of the different combinations of receptors within individual neurons compared 
between induced nociceptors and adult mouse nociceptors. In tdTomato-positive primary 
DRG neurons dissected and cultured from adult TrpV1::tdTomato mice, we found that 36% 
of the neurons responded to capsaicin, 2.5% to mustard oil and 2.5% to menthol 
(Supplementary Fig. 7b,c; n=249 tdTomato-positive cells that responded to KCl). Thus, the 
nociceptor lineage reprogramming not only yielded physiologically functional TrpV1, 
TrpA1 and TrpM8 proteins in the induced neurons, but the frequencies and combinations of 
the different receptors in the induced neurons closely mimicked those of adult mouse 
nociceptors.
While calcium imaging provides detailed information about calcium entry through Trp 
channels, it does not evaluate whether activation of these channel evokes action potential 
firing in the neurons. By culturing the induced neurons on extracellular multi-electrode 
arrays, we found that both capsaicin and mustard oil application evoked robust action 
potential firing from the induced neurons (Fig. 3c; 3/3 arrays for capsaicin and 3/3 arrays for 
mustard oil).
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We next used whole-cell patch clamp recordings to define the electrophysiological 
properties of the induced nociceptors and found that capsaicin (1 µM) elicited inward 
currents in 6/11 tdTomato-positive induced neurons, consistent with but somewhat higher 
than the calcium imaging results (Fig. 4a). The P2X3 subtype of ionotropic purinergic 
receptors is expressed specifically in nociceptor neurons32. Application of the P2X3-specific 
agonist α, β-methylene-ATP (30 µM) elicited rapidly-adapting inward currents in 8/16 
neurons (Fig. 4b) that were blocked completely by A-397491, a specific P2X3 antagonist, in 
4/4 neurons (not shown)33.
Perhaps the most nociceptor-specific functional marker is the TTX-resistant NaV1.8 sodium 
channel, which produces a portion of the current in the nociceptor action potential 
upstroke34. In voltage-clamp, we found that depolarizing voltage steps elicited inward 
sodium currents both before and after the application of 300 nM TTX (Fig. 4c; 14/15 
recorded induced nociceptors had TTX-resistant sodium currents greater than 50 pA). In 
agreement with our expression studies, the slow channel kinetics of the TTX-resistant 
currents are typical for NaV1.8 as opposed to the fast NaV1.5 cardiac sodium channel, 
which is present in developing embryonic nociceptors35. Furthermore, five of the 14 neurons 
with TTX-resistant sodium currents also exhibited a persistent sodium component, which 
previous studies have found to be due to NaV1.934,36 (Fig. 4c). The ability to generate 
action potentials in the presence of TTX is a feature of nociceptors but not of other DRG or 
central neurons. The induced neurons fired single TTX-resistant action potentials that 
overshot 0 mV in 7/12 neurons (Fig. 4d). NaV1.8 is responsible for the characteristic broad 
action potential shape of the nociceptor action potential8, which we found to be a property of 
the induced neurons (mean action potential width 3.32 ± 0.33 ms; n=13); as expected, adult 
primary tdTomato-positive nociceptors fired broad action potentials, but not large tdTomato-
negative primary non-nociceptor DRG neurons (Fig. 4e). In addition to differences in action 
potential morphology, the firing pattern of nociceptor neurons to prolonged depolarizing 
currents is tonic, compared to the phasic firing of most large A-β DRG neurons37. Induced 
nociceptors fired tonic action potential trains in response to depolarizing current steps in 
12/13 cells, consistent with the tonic firing found in tdTomato-positive adult primary mouse 
nociceptors, and in contrast to the single action potentials elicited in non-nociceptor, large 
tdTomato-negative adult DRG neurons (Fig. 4f).
While hyperpolarization-activated cyclic nucleotide-sensitive (HCN) currents are not 
specific for nociceptor neurons, they play an important role within these cells in neuropathic 
and inflammatory pain38, and thus their presence may be important for disease-modeling. 
We found that the induced nociceptors produced typical sag depolarizations in response to 
hyperpolarization (Fig. 4g) in 11/17 tdTomato-positive induced neurons, consistent with 
ZD7288-sensitive HCN currents recorded in voltage clamp (2/2, not shown).
A critical function of peptidergic neurons, most of which express TrpV17, is to release 
neuropeptides such as CGRP and Substance P. To assess the fidelity of the induced 
nociceptors in this capacity, we measured CGRP levels in supernatant following a 
depolarizing stimulus and found that induced nociceptors, but not BAM-derived neurons, 
released CGRP after KCl stimulation (Fig. 4h; n=4; Mann-Whitney U-test p=0.03). The 
concentrations of CGRP released by the induced neurons were comparable to those released 
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by primary DRG neurons (Supplementary Fig. 8), thus indicating that the induced neurons 
have synaptic vesicle release mechanisms in place.
Induced Nociceptors Model Inflammatory Sensitization
The transition from high-threshold baseline nociception to low-threshold clinical pain 
hypersensitivity commonly involves peripheral sensitization of nociceptors. For the induced 
nociceptors to be valuable in vitro models of in vivo pathophysiology, they must replicate 
not only the specific functional channels and receptors of the cells but also the process of 
sensitization that leads to pathological pain. Prostaglandin E2 (PGE2) activates the PKA 
pathway and sensitizes the TrpV1 receptor, reducing its threshold and decreasing 
desensitization15,16. In the tdTomato-positive induced neurons, a low concentration (300 
nM) of capsaicin rarely yielded a detectable response (mean change in fluorescence 
absorption ratio of 0.028 ± 3.0*10−3) (Fig. 5a,b). However, after treatment with PGE2 (1 
µM) for two minutes, a second identical capsaicin (300 nM) application yielded a mean 
response of 0.18 ± 6.0*10−3 (n=41 cells; paired t-test p=1.5×10−4). Plotting the magnitudes 
of the initial capsaicin and PGE2-sensitized capsaicin responses revealed that although the 
majority of neurons exhibited small or undetectable initial responses to capsaicin, they 
produced robust signals after PGE2 sensitization (Fig. 5c).
TrpV1 sensitization also may contribute to painful chemotherapy-induced neuropathy due to 
oxaliplatin17. Using MEA recording, we compared capsaicin responses in induced 
nociceptors treated with either 50 µM oxaliplatin or vehicle control, and found marked 
sensitization in the oxaliplatin-treated nociceptors (Fig. 5d,e).
Induction of Human Nociceptors
To derive nociceptors from human fibroblasts, we initially included NeuroD1 in the 
nociceptor induction protocol, as this transcription factor was important in prior human 
lineage reprogramming studies39. However, we found that the reprogramming efficiency, 
was greater without NeuroD1 (five factors) than with NeuroD1 (six factors) (20.7 ± 1.4 cells 
per field for five factors; 9.7 ± 1.1 cells per field for six factors, n=6 wells/group; t-test 
p=1.0×10−4) (Supplementary Fig. 9). Furthermore, more neurons exhibited larger sodium 
currents (67% of patched five factor neurons had peak transient sodium currents greater than 
500 pA, versus 29% of six factor neurons) and five factor neurons were healthier (resting 
Vm −49.3 ± 2.2 mV, n=33 five factor neurons; Vm −37.3 ± 3.2, n=20 six factor neurons; 
Mann-Whitney U-test p-value = 0.001). Using healthy control (HC) subject fibroblasts, the 5 
factors yielded Tuj1-positive neurons at an efficiency of 5% of plated fibroblasts, and 16% 
of the Tuj1-positive neurons were also peripherin-positive (Fig. 6a,b), efficiencies that were 
somewhat lower than the mouse induced nociceptors. A small number of the Tuj1-positive 
neurons were NF200-positive (Fig. 6c). We recorded from the neurons using whole-cell 
patch clamp. Although we did not have a reporter for a particular neuronal subtype, the 
induced human neurons fired broad action potentials (mean action potential width 3.88 ± 
0.41 ms; n=17; Fig. 6d), consistent with functional nociceptors. In 38 voltage clamp 
recordings, we applied TTX to neurons with a large total sodium current (greater than 1 nA) 
and detected TTX-resistant sodium currents in 10/10 neurons (Fig. 6e). As in both our 
mouse induced nociceptors and primary mouse and human nociceptors34,36, the induced 
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human neurons had different combinations of slow- and persistent TTX-resistant sodium 
currents, consistent with NaV1.8 and NaV1.9 contributions, respectively (Fig. 6e).
In order to evaluate the potential of the human neurons for disease modeling, we 
reprogrammed fibroblasts from three HC and three unrelated, age-matched subjects with 
familial dysautonomia (FD, hereditary sensory and autonomic neuropathy type III, Riley-
Day syndrome), due to a homozygous donor splice site mutation that results in deletion of 
intron 20 from the I-κ-β kinase complex-associated protein (IKBKAP) RNA40. We found 
that single FD-derived neurons picked using patch pipettes exclusively expressed the 
abnormally spliced transcript, something not previously identified, while the HC-derived 
neurons expressed only the normal transcript (Fig. 6f). FD fibroblasts expressed a mixture of 
abnormally spliced and normal transcripts, consistent with prior studies41,42, while HC 
fibroblasts expressed only the normal transcript (Fig. 6f; Supplementary Fig. 10).
Although we detected peripherin-positive, Tuj1-positive neurons from all HC and FD 
subjects (Fig. 6g,h), the neurons from FD subjects showed a trend toward decrease in 
number (Fig. 6i; 16.5 ± 1.1 HC neurons/well, n=60 wells; 14.1 ± 1.1 FD neurons/well, n=60 
wells; difference between HC neurons/well and FD neurons/well 2.3 ± 1.5, n=60 wells; 
random intercept mixed-effects model p=0.26) and a robust reduction in neurite outgrowth 
per cell (Fig. 6j; 725 ± 24 µm per HC neuron, n=60 wells; 433 ± 25 µm per FD neuron, n=60 
wells; difference between HC neuron outgrowth per cell/well and FD neuron outgrowth per 
cell/well 291.3 ± 32.6 µm, n=60 wells; random intercept mixed-effects model p=0.012), as 
well as number of branches per neuron (Fig. 6k; 7.9 ± 0.3 branches per HC neuron, n=60; 
4.7 ± 0.3 branches per FD neuron, n=60 wells; difference between HC braches per neuron/
well and FD branches per neuron/well 3.3 ± 0.4, n=60 wells; random intercept mixed-effects 
model p=0.017) compared to HC-derived neurons.
DISCUSSION
The subjective nature of pain as a human experience confounds its clinical study, raises 
questions about the relevance of animal models and complicates the development of 
effective treatments43. Furthermore, limited physiological studies of primary human 
nociceptors highlight differences between human and rodent nociceptors, including the 
function of individual channels and receptors as well as their distribution within different 
nociceptor subtypes44, and thus emphasize the importance of investigating human 
nociception using human nociceptors. Modeling key mechanistic aspects of human pain 
processing with derived human cells may enable phenotypic screens for analgesics based on 
basal and sensitized neurons from chronic pain subjects. Such approaches would improve 
upon current drug screens that employ heterologously-expressed targets in non-neuronal 
cells and consequently do not reflect the native scaffolding and molecular signaling present 
in human neurons, the pathophysiological changes that drive clinical pain and genetic 
backgrounds that may increase pain susceptibility.
We find that a small number of transcription factors can quite efficiently convert fibroblasts 
into neurons that express the key specific functional receptors found in bona fide adult 
nociceptors. While TrpV1 is expressed in a tiny fraction of central neurons30, NaV1.8 and 
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TrpA1 are not expressed within the central nervous system. The collective expression of 
subsets of these markers defines specific subpopulations7, and indeed to a first 
approximation, our neurons recreate the combinatorial patterns that define the diversity of 
TrpV1-expressing nociceptive neuronal cohorts found in primary mouse nociceptors. 
Interestingly, we seem not to have derived a single nociceptor type but instead have 
engineered multiple subtypes of cells with properties and frequencies similar to those found 
in vivo. Three possible explanations will need to be investigated in future studies: first, there 
may be an autonomous program driving the native lineage diversity that is replicated by our 
transcription factors; second, non-cell autonomous communication among neurons could 
influence their identify; third, different identities could reflect different relative levels of 
transcription factor expression.
While the transcription factor combinations that facilitate induction of specific fates have 
typically incorporated factors known to play defined roles in the development of those 
neurons1, some of the factors we used do not have any well-defined developmental role. We 
chose Isl2 due to its strong differential expression in FACS-sorted nociceptors compared to 
proprioceptors and an expression pattern similarity to NaV1.827, although nothing is known 
about its role in nociceptor development. Interestingly, the in situ expression of Isl2 appears 
much more nociceptor-specific than that of Isl127,28, for which a role in nociceptor 
development and TrpV1 expression has been documented24, although another report found 
broader RNA expression of Isl245. Our results also raise questions as to why specific 
transcription factors facilitate or inhibit the reprogramming both to neuronal and nociceptor 
lineages. In contrast with prior studies4,5,39, we found that Brn2 inhibited lineage 
reprogramming of mouse fibroblasts to neurons, and NeuroD1 decreased the efficiency and 
quality of human neurons. With regard to the nociceptor lineage, the roles of Brn3a and Klf7 
in maintaining TrkA expression during embryonic development appear similar in the 
literature22,25. However, we found that Brn3a markedly inhibits lineage reprogramming to 
nociceptors while Klf7 promotes it. Runx1, which is active and critical in the later 
embryonic stages of nociceptor development, does not facilitate the reprogramming process. 
Ngn1 has a well-characterized role in nociceptor development and eventual TrpV1 
expression21, but is involved much earlier in development (E9–E13) compared to the other 
studied factors20. Thus, while developmental studies may inform the choice of transcription 
factors for lineage reprogramming, reprogramming studies may themselves provide insight 
into important developmental pathways and their regulators, recognizing of course that 
reprogramming may not recapitulate transcription factors expressed in normal development.
The intricacy and specificity of primary nociceptor neuron physiology and the fortunate 
ability to culture adult primary sensory neurons provide an unusual and well-controlled 
opportunity to evaluate how closely lineage-reprogrammed neurons resemble the molecular 
expression, function and maturity of primary adult neurons. We found that the 
reprogrammed neurons produced functional TrpV1, TrpA1 and TrpM8-expressing neurons 
in similar relative percentages to those found in primary tdTomato-positive adult mouse 
nociceptors. In addition, the induced neurons yielded not only functional TTX-resistant 
action potentials, but also the broad action potential morphology and phasic firing pattern 
characteristic of nociceptors. Indeed, their function globally was remarkably close to that of 
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adult primary nociceptors by every measure we made, although we cannot exclude other 
contributions, such as neuronal maturity, to firing pattern and action potential morphology. 
Future studies will explore the synaptic capacity, neurotrophin dependence, and requirement 
for sustained viral transgene expression in the derived nociceptors.
Patient-derived neurons would have optimal utility as a drug screening tool if the derived 
neurons replicate the sequence of pathophysiological events that result in specific clinical 
diseases. Reprogrammed nociceptors may be particularly useful as an in vitro model for 
pain, because the pain sensitization process mimicked by the induced nociceptors is one of 
the major factors that drive the transition to pathological pain. The development of a 
fluorescent nociceptor-specific marker will enable further optimization of human induced 
nociceptor maturation as well as more extensive molecular and physiological 
characterization of the human neurons. Whether nociceptors reprogrammed from individuals 
with chronic pain or peripheral neuropathy will reveal phenotypic differences compared to 
control subject-derived nociceptors can be evaluated in future research.
Analysis of FD patient tissue samples40,41 and FD iPSC-derived neural precursors42 have 
consistently shown the presence of both abnormally and normally spiced transcripts in the 
same sample. The detection of both splice forms could reflect either the presence of both 
normal and aberrant splicing in the affected neuronal types or simply the heterogeneity of 
affected and unaffected tissue types in the samples. Our finding that the normal IKBKAP 
splice variant is apparently absent in the FD-derived neurons indicates the latter is likely the 
case and may have implications regarding the extent of splice correction necessary for 
disease treatment, and may explain the observation in a mouse FD model that small amounts 
of IKAP are sufficient to revert the phenotype46. The reduction in outgrowth and branching 
in familial dysautonomia compared to control-derived neurons may reflect the presence of 
processes similar to those responsible for the progressive decrease in unmyelinated sensory 
neurons that is observed clinically40 and the loss of TrkA-positive neurons in a mouse 
model47. The ability to obtain FD nociceptors from patient fibroblasts will facilitate future 
studies to examine the mechanisms of disease and to screen and evaluate potential 
treatments. Our experiments illustrate how derived neurons with major features of primary 
nociceptors can be generated and employed as a model for “pain a dish”.
Online Methods
A methods checklist is available with the supplementary materials.
Fibroblasts
TrpV1-Cre+/−::tdTomato+/− transgenic mice were generated by crossing TrpV1-Cre+/+ 
mice with tdTomato+/+ reporter mice on a C57Bl6 background (both from Jackson 
Laboratories). Mouse embryonic fibroblasts (MEFs) were harvested from TrpV1::tdTomato 
embryos, of either gender, at E12.5, passaged once and frozen at −120°C. Human fibroblasts 
(all from Coriell Institute) were obtained from three healthy control subjects (GM00969, 2 
year old Caucasian female; GM03348, 10 year old Caucasian male; GM00316, 12 year old 
Caucasian male) and from three age-matched subjects with familial dysautonomia 
(GM04663, 2 year old Caucasian female; GM04959, 10 year old Caucasian female; 
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GM04899, 12 year old Caucasian female). The use of human lines was approved under the 
Boston Children’s Hospital Institutional Review Board.
Viruses and transductions
Complimentary DNAs for the 9 candidate factors (obtained from the Dana Farber/ Harvard 
Cancer Center DNA Resource Core except Ngn1, Tlx3 and Runx1, which were obtained 
from Q. Ma) were each cloned into the pMXs retroviral expression vector modified to 
contain a WRE using Gateway technology (Invitrogen). 293T cells were co-transfected with 
individual viruses and pHDMG and pIKLMV packaging plasmids using Lipofectamine 
2000 (Life Technologies). Media was changed to new DMEM (GIBCO), 20% FBS 
(Invitrogen), 50 U/mL Penicillin/Streptomycin (CellGro) after 16 hours. At that time, 
fibroblasts were thawed and plated on 24-well plates (25K cells/well), 6-well plates (150K 
cells/well), 35mm dishes (150K cells/well), or p515A multi-electrode array (MEA) probes 
(Alpha Med Scientific) (12K cells/MEA) that were previously coated with poly-D-lysine 
(Sigma), gelatin (Cell Signaling) and laminin (Sigma). Viruses were harvested 24 hours 
later, concentrated approximately 5 fold using Amicon ultra centrifugal filter units 
(Millipore) and applied to fibroblasts with 5 µg/ml polybrene (Sigma) (Day 0, transduction). 
Cortical mouse glia obtained from P0–P2 C57Bl6 mice were added on Day 2 for all but the 
calcium imaging experiments. Media was switched on Day 4 to N3 media: DMEM/F-12 
(GIBCO), N2 and B27 supplements (Life Technologies), glutaMAX (Invitrogen), pen/strep, 
FGF (20 ng/mL, Millipore) with 5% FBS, along with the neurotrophic factors BDNF, 
CNTF, GDNF (R&D Systems) at 10 ng/ml each. The TGFβ-Inhibitor RepSox (7.5 µM; 
Millipore), which has been shown to improve survival of different neuronal types over long-
term culture (Ichida and Eggan, unpublished), was added for calcium imaging and human 
transductions. Media was changed every two days, and on Day 10, NGF was also added to 
the media (50 ng/mL; Invitrogen).
Immunohistochemistry
Cells were fixed with 4% paraformaldehyde (PFA), washed three times with 1× PBS, 
incubated in blocking buffer (1% Blocking Reagent (Roche), 0.5% BSA, 0.1% TritonX-100) 
for one hour at room temperature and stained with primary antibodies overnight at 4°C in 
blocking buffer. The next day the cells were washed three times with 1× PBS, stained with 
secondary antibodies for one hour at room temperature and washed three times with 1× PBS 
before imaging, which was performed using the microscope setup described below.
Primary antibodies included: mouse anti-β tubulin III (Sigma T8660, 1:1000, validated51), 
rabbit anti-peripherin (Millipore AB1530, 1:800, validated52), rabbit anti-TrpV1 (Alomone 
Labs ACC-030, 1:200, validated53), rabbit anti-CGRP (Calbiochem/Millipore PC205L, 
1:300, validated54), chicken anti-neurofilament, heavy chain (Millipore AB5539, 1:1000, 
validated55), mouse anti-Nestin (Abcam ab6142, 1:500, validated56), mouse anti-smooth 
muscle actin (Sigma A5228, 1:300, validated57), goat anti-Sox1 (Santa Cruz #SC17317, 
1:50, validated58), mouse anti-Ki67 (Sigma P6834, 1:500, validated59). Secondary 
antibodies included: goat anti-chicken AlexaFluor 568 (Life Technologies A11041), goat 
anti-chicken AlexaFluor 488 (Life Technologies A11039), goat anti-mouse AlexaFluor 488 
(Life Technologies A11029), goat anti-mouse AlexaFluor 568 (Life Technologies A11031), 
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goat anti-rabbit AlexaFluor 488 (Life Technologies A11008), goat anti-rabbit AlexaFluor 
568 (Life Technologies A11011), donkey anti-goat AlexaFluor 488 (Life Technologies 
A11055).
Primary DRG culture
DRGs were dissected from adult TrpV1-Cre::tdTomato mice (12–13 weeks) into Hank’s 
balanced salt solution (HBSS) (Life Technologies). DRG were dissociated in 1 mg ml−1 
collagenase A plus 2.4 U ml−1 dispase II (enzymes, Roche Applied Sciences) in HEPES-
buffered saline (Sigma) for 90 min at 37 °C and then triturated down to single cell level 
using glass Pasteur pipettes of decreasing size. DRGs were the centrifuged over a 10% BSA 
gradient and plated on laminin-coated cell culture dishes (Sigma). DRGs were cultured 24 
hours in B27-supplemented neurobasal-A medium plus 50 ng/ml NGF (Invitrogen), 2 ng/ml 
GDNF (Sigma), 10uM arabinocytidine (Sigma) and penicillin/streptomycin (Life 
Technologies).
qPCR
To compare expression levels of select genes in TrpV1-tdTomato-positive induced 
nociceptors, TrpV1-tdTomato-positive primary DRGs and TrpV1-tdTomato MEFs, 
individual tdTomato-positive neurons and fibroblasts were picked using a micropipette. 
RNA was harvested from sets of 50 cells with the RNeasy Micro Kit (Qiagen) and reverse 
transcribed with SuperScript VILO cDNA synthesis kit (Life Technologies). Quantitative 
PCR was completed using mouse-specific TaqMan Gene Expression Assays (Life 
Technologies) and the TaqMan Gene Expression Master Mix (Life Technologies). A 
minimum of two technical replicates for each of three biological replicates (independent cell 
collections) were completed for each gene.
Single cell RT-PCR
Single human induced nociceptors were picked using individual patch pipettes and placed 
into Single Transcript Amplification (RT-STA) mixture from the CellsDirect One-Step 
qRT-PCR Kit (Life Technologies) using primers for normally and aberrantly spliced 
IKBKAP39 and GAPDH. RT-STA reaction products were used for PCR using the same 
IKBKAP and GAPDH primers and resulting products were run on 1% agarose gels.
Calcium imaging
Cells were loaded with Fura2-AM (10ug/mL, Molecular Probes) by incubating at room 
temperature for one hour and then de-stained for 15 minutes in saline. For primary DRGs 
from adult TrpV1-Cre+/−::tdTomato+/− mice, cells were imaged after 24 hours in culture 
using an identical protocol. Cells were imaged using a Nikon Eclipse Ti microscope with a 
Xenon lamp, Andor DL-604M camera and standard 340 nM and 380 nM filters controlled 
by a Ludl Mac6000 shutter using Nikon Elements software. Exposure times were 300–600 
ms and images were taken every three seconds. One minute of baseline imaging was 
recorded prior to the addition of the agonists, during which control vehicle was applied after 
30 seconds (not shown). Menthol (250 µM) was applied at one minute, followed by Mustard 
oil (100 µM) at two minutes and Capsaicin (1 µM) at three minutes and finally KCl (40 mM) 
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at four minutes. For Trp channel experiments, each agonist was applied for 20 seconds and 
then washed out with external solution. In the PGE2 sensitization experiments, capsaicin 
(300nM) was applied for 20 seconds after two minutes of recording, followed immediately 
by PGE2 (1µM) for two minutes, a conditioned capsaicin (300nM) application for 20 
seconds and KCl (40 mM) after 4.5 minutes. Analysis of tdTomato positive cells was 
performed using custom Matlab (Mathworks) software to include cells that responded to 
KCl (1.5 × baseline), had a stable baseline during control vehicle application and a response 
to agonist with an amplitude of at least 10% of baseline, with subsequent agonist responses 
required to be both at least 10% of initial baseline and 10% above a second baseline value 
obtained during the immediately preceding wash period.
CGRP ELISA
Induced nociceptors, BAM-derived neurons and primary DRGs were exposed to KCl (20 
mM, 40 mM, 60 mM, or 80 mM), capsaicin (0.1 µM), or vehicle for 10 minutes at 37°C. 
The supernatants were collected and analyzed using the Rat CGRP Enzyme Immunoassay 
Kit (Bertin Pharma/Cayman Chemical, #589001). Plates were read at 405nm for 0.1s on a 
Wallac Victor2 1420 Multilabel Counter (Perkin Elmer), and data were analyzed using the 
Wallac 1420 Workstation.
MEA recording
TrpV1-Cre+/−::tdTomato+/− MEFs were plated on poly-D-lysine/laminin coated p515A 
probes (Alpha Med Scientific) at typical densities of 12,000 cells per probe, transduced with 
retroviruses and cultured for four weeks. Recordings from 64 extracellular electrodes were 
made using a Med64 (Alpha Med Scientific) MEA recording amplifier with a head stage 
that maintained a temperature of 37°C. Data were sampled at 20 kHz, digitized, and 
analyzed using Mobius software (Alpha Med Scientific) with a 2 kHz 9-pole Bessel low 
pass filter using a sodium-based extracellular solution: 135 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES 10, pH 7.4. The probes were recorded 
for one minute before the application of the agonists to obtain a baseline and two minutes 
after the application of capsaicin (1 µM concentration) or mustard oil (100 µM), which were 
applied at a 10× concentration at the edge of the well (far from the electrodes). Three 
replicates for each agonist, capsaicin and mustard oil, were completed from two separate 
transductions. For oxaliplatin sensitization experiments, cells were treated with either 50 µM 
oxaliplatin or vehicle control for 10 minutes and then recorded for one minute during 
treatment with 300 nM capsaicin.
Patch electrophysiology
Whole-cell patch recordings were performed on induced tdTomato-positive nociceptors, 
derived from TrpV1-Cre+/−::tdTomato+/− MEFs, four–five weeks post-transduction and 
assessed for responses to capsaicin and α,β-methylene ATP (30 µM, Sigma), total and TTX 
(300 nM, Sigma) -resistant sodium currents, HCN depolarizating current sags and action 
potentials. Whole-cell current-clamp and voltage-clamp recordings were performed using a 
Multiclamp 700B (Molecular Devices) at room temperature (21–23°C). Data were sampled 
at 20 kHz and digitized with a Digidata 1440A A/D interface and recorded using pCLAMP 
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10 software (Molecular Devices). Data were low-pass filtered at 2 kHz. Patch pipettes were 
pulled from borosilicate glass capillaries on a Sutter Instruments P-97 puller and had 
resistances of 2–4 MΩ. The pipette capacitance was reduced by wrapping the shank with 
Parafilm and compensated for using the amplifier circuitry. Series resistance was 5–10 MΩ 
and compensated by at least 80%.
For voltage-clamp recordings, voltages were elicited by 200-ms depolarizing steps from a 
holding potential of −80 mV to test potentials ranging from −100 mV to 30 mV in 10 mV 
increments. Responses to capsaicin (1 µM) and α,β-methylene ATP (30 µM) were measured 
in voltage clamp at a holding potential of −80 mV. Electrode drift was measured at the end 
of each recording and was typically 1–2 mV. The potassium-based intracellular solution 
contained 150 mM KCl, 2 mM MgCl2, 10 mM HEPES, 4 mM MgATP, 0.3 mM NaGTP, 10 
mM Na2PhosCr, 1mM EGTA, pH 7.4. For isolation of voltage-gated sodium currents 
internal KCl was replaced by CsCl to block potassium currents and 100 µM CdCl2 was 
applied to block calcium currents. 300 nM TTX was used to block TTX-sensitive voltage-
gated sodium channels. HCN currents were measured by sequential hyperpolarizing steps in 
current clamp with an increment of −10 pA steps.
Quantification of cell number, axon length and axonal branching
All quantifications of cell count and morphological properties were performed by a 
researcher blind to genotype/condition. Reprogramming efficiency and percentage of 
TrpV1::tdTomato-positive, Tuj1-positive, peripherin-positive and CGRP-positive neurons 
were determined using MetaXpress software. The number of TrpV1::tdTomato-positive 
(mouse, minimum of 3 wells from each of three separate transdifferentiations) and Tuj1-
positive (human, minimum of 12 wells from each of three separate transdifferentiations) 
neurons was divided by the number of fibroblasts plated to calculate the reprogramming 
efficiency. Axon length and branching were quantified from the six age-matched human 
fibroblast lines (three HC and three FD) with images from eight wells (two transductions) 
and four wells (one transduction) of each line (20 wells total/line).
To quantify the number of TrpV1-tomato-positive neurons resulting from infection of 
different combinations of transcription factors, tomato-positive neurons were counted by 
hand in at least four separate wells for each condition from two separate transductions and 
averaged (Fig. 1, Supplementary Fig. 4). Due to the variability of retroviral transductions 
with large numbers of viruses, we did not quantify experiments with transductions of 11–12 
viruses at once (Supplementary Fig. 3). For comparison of 5 Factors ± NeuroD1, images 
were taken of 6 wells of each condition from one transduction.
Statistical Analyses
Figures show mean ± SEM for all analyses; all tests are two-tailed using a significance 
threshold of 0.05. We used a Mann-Whitney U test to evaluate CGRP release after log 
transformation to equalize variance between groups (Fig. 4h). This gave a W statistic of 16 
(4 assays/group) and p-value of 0.03. We used a paired t-test to evaluate baseline and PGE2-
sensitized capsaicin responses in the induced mouse nociceptors (Fig. 5a). This gave a T 
statistic of 4.61 with 20 degrees of freedom (21 cells) and a p-value of 9.7*10−4. For 
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comparison of transdifferentiation efficiency using 5 vs 6 factors, we used an unpaired t-test 
to compare average number of cells/field in 6 wells/group and got a T statistic of 6.1 with 10 
degrees of freedom and p-value 1.0*10−4 (Supplementary Fig. 9).
For morphological analyses of human HC and FD-derived neurons, we performed analyses 
of cell number, axonal outgrowth, and number of branches (Fig. 6). Distribution of cell 
number and number of branches were not normal (Shapiro-Wilk test). We looked at the 
distribution of all the measures graphically and found that they are approximately normal. 
Variance of cell number, axon outgrowth, and number of branches were not different 
between HC and FD-derived neurons (Levene test). Using random intercept model and 
taking matching of cell lines into account provided FD disease effect estimates (standard 
errors) compared to HC: −2.3 (1.5) cell numbers, p=0.2632; −291.3 (32.6) µM axon 
outgrowth/cell, p=0.0123; −3.3 (0.4) branches/cell, p=0.0165. Post-hoc analysis to compare 
individual lines was performed using Tukey-Kramer for the three pairs of lines. 
Comparisons of FD line 1 to matched HC line 1 gave estimate of differences as 2.1 (cells), 
−292.3 (outgrowth), −3.5 (branches) respectively. Comparisons of FD line 2 to matched HC 
line 2 gave estimate of differences as −7.2 (cells), −274.7 (outgrowth), −3.2 (branches) 
respectively. Comparisons of FD line 3 to matched HC line 3 gave estimate of differences as 
−1.9 (cells), −307.1 (outgrowth), −3.1 (branches) respectively. However, the model with 
interaction parameter for cell line type and disease group only provided generalized inverse 
estimates of the standard errors. Hence, the confidence intervals and p-values for these 
individual cell lines are not reported. All statistical analyses were performed in software R 
ver 3.1.0 and SAS ver 9.1 (Cary, NC). No power analyses were used to pre-determine 
sample sizes, but our sample sizes are similar to those used by others in the field.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Combinations of transcription factors result in nociceptor production. (a) Few tdTomato, 
Tuj1-positive neurons are produced by the combination of six factors (6 TFs): Brn2, Ascl1, 
Myt1l, Ngn1, Isl2 and Klf7. (b) Removal of Brn2 markedly increases the number of 
tdTomato, Tuj1-positive neurons. (c–g) Omission of Ascl1 (c), Myt1l (d), Ngn1 (e), Isl2 (f) 
or Klf7 (g) from the six factors disrupts the generation of nociceptor neurons. Representative 
images for each transcription factor drop out were taken from n=4 wells from two separate 
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transductions. Scale bars: 100 µm. (h) Quantification of the single factor dropout studies 
from n=4 wells from each of two separate independent transductions for each category.
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Figure 2. 
Induced nociceptors (iNoc) express characteristic nociceptor genes. (a,b) Tuj1 (a) and 
TrpV1 (b) expression in fibroblast-derived nociceptor neurons. (c) Most induced nociceptors 
stain for the C-fiber marker peripherin (Prph). (d) A number of induced nociceptors express 
the peptidergic-marker CGRP. (e) A small number of induced nociceptors express the 
intermediate filament marker NF200 found in myelinated fibers. Representative images 
were selected from immunostaining that was repeated in n=4 wells from two independent 
transductions. Scale bars: 100 µm. (f) RT-qPCR data showing expression levels of 
nociceptor-specific genes in 50-picked tdTomato-positive primary adult mouse nociceptors 
(DRGs, black circles) and 50-picked tdTomato-positive induced nociceptors (red circles), 
relative to their levels in MEFs, from a minimum of two independent biological replicates 
(biological replicates represented as independent circles).
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Figure 3. 
Induced neurons respond to different Trp channel agonists. (a) Sample calcium imaging 
responses to sequential application of menthol (250 µM), mustard oil (100 µM), capsaicin (1 
µM), and potassium chloride (40 mM) in a single dish of induced tdTomato-positive derived 
nociceptors. Traces are representative recordings from n=227 tdTomato-positive / KCl-
responding cells cultured in 19 dishes from 3 independent transductions (b) Venn diagram 
showing subgroups of tdTomato-positive cells that responded to KCl (40 mM, grey), 
capsaicin (Cap, 1 µM, red, 39%), mustard oil (MO, 100 µM, lower small circle, green, 9%) 
and menthol (ME, 250 µM, upper small partial circle, blue, 3%; note that no tdTomato-
positive cells responded to menthol alone) (c) Sample electrodes from extracellular multi-
electrode array recordings of induced neurons before (left) and after (right) the application 
of capsaicin (1 µM, upper) and mustard oil (100 µM, lower). Sample recordings for each 
agonist are indicative of results from three experiments across two independent 
transductions, in which all replicates showed an increase in firing after agonist application.
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Figure 4. 
Whole-cell patch clamp recordings of tdTomato-positive induced nociceptors. (a) Current 
recording in response to treatment with 1 µM capsaicin (6/11 induced neurons responded). 
(b) Current recording following the application of 30 µM α, β-methylene-ATP (8/16 induced 
neurons responded). (c) Inward currents following step depolarization before (left) and after 
(middle) the application of 300 nM tetrodotoxin (TTX) (14/15 induced neurons had TTX-
resistant sodium currents greater than 50 pA). Right panel shows a different neuron without 
a persistent TTX-resistant sodium current (d) Action potential firing elicited by depolarizing 
current in the presence of 300 nM TTX (7/12 cells fired single TTX-resistant action 
potentials with peak greater than 0 mV). (e, f) Examples of individual action potentials (e) 
and trains (f) elicited from induced nociceptors (iNoc), tdTomato-positive primary adult 
nociceptors (Primary noc) and tdTomato-negative primary adult non-nociceptors (Primary 
non-noc) (12/13 induced neurons fired tonically). (g) Examples of sag depolarizations in 
response to hyperpolarizing current injections in induced nociceptors (11/17 induced 
neurons produced a sag depolarization). (h) CGRP was released from induced nociceptors 
(5F), but not BAM-derived neurons, in response to KCl (80 mM), but not vehicle. Mean 
(SEM) for 5F and BAM following KCl stimulation are 390.4 (52.5) and 10.3 (2.6) pg/ml 
(n=4; Mann-Whitney U-test p=0.03).
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Figure 5. 
Sensitization of induced nociceptors treated with the inflammatory mediator PGE2 and the 
chemotherapeutic drug oxaliplatin. (a) Sample calcium imaging recordings of induced 
nociceptors treated with 300 nM capsaicin before and after treatment with 1 µM PGE2 from 
recordings of n=41 tdTomato-positive / KCl-responding cells. (b) Plot of individual and 
mean response amplitudes for initial and PGE2-sensitized capsaicin treatments (paired t-test 
p=1.5×10−4). (c) Plot of initial versus PGE2-sensitized capsaicin response amplitudes for 
individual induced neurons. (d) Sample traces from extracellular multi-electrode array 
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recordings of induced neurons in response to 300 nM capsaicin following 10 minute 
exposure to vehicle control (n=5 MEAs) or oxaliplatin (50 µM; n=4 MEAs) on induced 
neurons from two separate transductions. (e) Quantification of spikes per minute from 
induced nociceptors in response to capsaicin alone (control) and capsaicin following 
oxaliplatin treatment. Error bars are ± SEM.
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Figure 6. 
Human fibroblast-derived neurons for human disease modeling. (a) Low magnification of 
Tuj1 (left) and peripherin (Prph, right) staining of healthy control (HC)-derived neurons. 
Scale bars: 500 µm. (b) High magnification of Tuj1 staining of HC-derived neurons. Scale 
bar: 100 µm. (c) NF200-positive cell derived from HC fibroblasts. (d) Current recording of 
an action potential train from a HC-derived neuron (17/33 induced neurons with peak Na 
current > 500 pA fired at least one action potential with peak greater than 0 mV). (e) Total 
(left) and TTX-resistant (middle) sodium currents from a single HC-derived neuron. Right 
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panel shows persistent TTX-resistant sodium current recordings from a separate HC-derived 
neuron characteristic of Nav1.9. (f) RT-PCR for IKBKAP and GAPDH from single human 
induced neurons (left) and single human fibroblasts (right) show normal (black arrow) and 
abnormally spliced (red arrowhead) transcripts. Full-length gels are presented in 
Supplementary Fig. 10. (g) Low magnification of Tuj1 (left) and peripherin (right) staining 
of neurons derived from a patient with Familial Dysautonomia (FD). Scale bars: 500 µm. (h) 
High magnification of Tuj1 staining of FD-derived neurons. Scale bar: 100 µm. For all 
images, representative images were selected from human neurons generated in n=6 wells 
from three separate transductions. (i) Quantification of Tuj1-positive neurons in HC and FD-
derived nociceptors (random intercept mixed-effects model p=0.26). (j) Neurite outgrowth 
per cell for HC and FD-derived Tuj1-positive nociceptors (random intercept mixed effects 
model p=0.012). (k) Number of branches per cell for HC and FD-derived Tuj1-positive 
nociceptors (random intercept mixed effects model p=0.017). For i–k, images were analyzed 
from three pairs of age-matched HC and FD patient lines from each of three separate 
transductions (n=20 wells/line). Error bars are ± SEM.
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